Here are the Form 4 insider transactions from Opko Health Inc. (OPK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OPK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPK filings page.
OPKO HEALTH, INC. (OPK) director John A. Paganelli sold 4,426 common shares directly on November 5, 2026, at $1.78 per share; he reported 389,914 directly held shares afterward. Securities owned by his spouse were also sold: 9,175 shares at $1.82 per share, with zero shares reported afterward for that indirect holding. Paganelli disclaims beneficial ownership of the spouse-owned securities except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
OPKO Health, Inc. reported that Sr. Vice President and CFO Adam Logal had 53,266 shares of common stock withheld on July 24, 2026 at $1.22 per share to satisfy tax withholding on vesting of restricted stock units. After this tax-withholding disposition, he directly owns 563,396 shares.
OPKO HEALTH, INC. executive VP-Administration and director Steven D. Rubin reported a tax-related share withholding. On 2026-07-24, 53,266 shares of common stock were withheld at $1.22 per share to satisfy tax obligations on vested restricted stock units, leaving 6,571,966 shares directly owned.
OPKO Health director Prem A. Lachman received a new stock option grant. On June 18, 2026, he was awarded options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. These options are compensation-related, not an open-market purchase, and bring his directly held option position reported in this filing to 30,000 derivative shares.
OPKO Health director Roger Medel received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation. The options have an exercise price of $1.42 per share, become exercisable starting on 2027-06-18, and expire on 2036-06-17. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director Richard C. Pfenniger Jr. received a grant of stock options representing 60,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. After this award, he holds 60,000 derivative securities directly.
OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036.
According to the footnote, on June 18, 2026 the company canceled a prior grant of 50,000 options, granted 30,000 new options, and reissued 50,000 options, resulting in 80,000 options held directly after this award.
OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, were granted on June 18, 2026, and become exercisable starting June 18, 2027 with an expiration date of June 17, 2036. Following this grant, she holds stock options for 30,000 shares directly.
Opko Health director John A. Paganelli bought 10,000 shares of common stock in an open-market purchase at $1.135 per share. After this transaction, he directly holds 394,340 shares. An additional 9,175 shares are owned by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest.
OPKO HEALTH, INC. director Uppaluri Subbarao V received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.17 per share and were awarded at no cost to the director. According to the filing, these options become exercisable on March 18, 2027 and expire on March 17, 2036. Following this grant, the director holds stock options for 50,000 underlying shares.